Contraindicated (1)bortezomib will raise the stage or outcome of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or average CYP2C19 inhibitors may possibly improve mavacamten systemic exposure, resulting in heart failure as a consequence of systolic dysfunction. Ask your health care provider When you have questions about forms of https://elleryg555ufq7.mywikiparty.com/user